Adlai Nortye, Omada Health, Syndax, Six Flags, and Immunic Lead Market Declines

• Several stocks recorded double-digit losses on October 13, 2026.

• A failed clinical trial drove the decline in Syndax Pharmaceuticals.

• Six Flags shares fell following a fatal roller-coaster incident, while no clear catalysts were identified for the other declines.

On October 13, 2026, Adlai Nortye (NASDAQ: ANL) fell 17.3% to $11.76 on about 958,000 shares. No company-specific news clearly explained the decline.

Omada Health (NASDAQ: OMDA) dropped 16.3% to $18.30, with approximately 2.8 million shares traded. The company plans to report third-quarter results after the market closes on November 5, 2026, but the announcement did not explain the selloff.

Syndax Pharmaceuticals (NASDAQ: SNDX) declined 15.7% to $13.95. Its Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint, prompting the company to end development of the drug for that indication.

Six Flags Entertainment (NYSE: FUN) fell 14.4% to $10.20 after a fatal roller-coaster incident at Six Flags Over Georgia. The company temporarily closed nine similar coasters across six North American parks.

Immunic (NASDAQ: IMUX) declined 13.3% to $6.89 on approximately 572,000 shares. No new company announcement was identified as a clear cause of the drop.